{"id":"prtimes-41228","slug":"prtimes-41228","canonical_name":"ユナイテッド・イミュニティ株式会社","entity_type":"business","schema_org_type":"Organization","canonical_url":"https://ida.washinmura.jp/prtimes-41228","sameAs":["http://unitedimmunity.co.jp","https://www.houjin-bangou.nta.go.jp/henkorireki-johoto.html?selHouzinNo=6190001025121"],"public_ids":{"sameAs":["http://unitedimmunity.co.jp"],"citation":{"v":1,"faq":[{"a":{"en":"United Immunity is a global drug discovery firm in innate immunity. It acquired technical assets from Carisma Therapeutics to integrate into its Myeloid Targeting Platform, advancing in vivo CAR-M therapies for solid tumors with improved safety.","ja":"ユナイテッド・イミュニティは、自然免疫分野のグローバル創薬企業。Carisma Therapeuticsから技術資産を買収し、自社のP-LNP技術と融合、次世代CAR-M治療の開発を加速。","ko":"ユナイテッド・イミュニティ株式会社의 IDA 공개 프로필입니다.","zh":"United Immunity 是一家專注於先天免疫的全球藥物研發公司。近日完成收購 Carisma Therapeutics 的技術資產，整合至其 Myeloid Targeting Platform™，以提升針對實體癌的體內 CAR-M 療法效果並降低細胞激素釋放症候群風險。"},"q":{"en":"What is ユナイテッド・イミュニティ株式会社?","ja":"ユナイテッド・イミュニティ株式会社とは？","ko":"ユナイテッド・イミュニティ株式会社은(는) 어떤 곳인가요?","zh":"ユナイテッド・イミュニティ株式会社是什麼？"}},{"a":{"en":"Identity cross-verified via 1 linked sources incl. official site (see below).","ja":"公式サイト等 1 件の関連リンクで身分を相互検証しています（下記参照）。","ko":"공식 사이트 등 1개의 관련 링크로 신원을 상호 검증합니다(아래 참조).","zh":"透過官網等 1 個關聯連結相互驗證身分（見下方）。"},"q":{"en":"Official site & verified links?","ja":"公式サイト・関連リンクは？","ko":"공식 사이트·관련 링크는?","zh":"官網與關聯連結？"}}],"kind":"business","title":"ユナイテッド・イミュニティ株式会社｜企業情報・公式リンク","booking":[{"url":"http://unitedimmunity.co.jp","name":"公式サイト"}],"summary":{"en":"United Immunity is a global drug discovery firm in innate immunity. It acquired technical assets from Carisma Therapeutics to integrate into its Myeloid Targeting Platform, advancing in vivo CAR-M therapies for solid tumors with improved safety.","ja":"ユナイテッド・イミュニティは、自然免疫分野のグローバル創薬企業。Carisma Therapeuticsから技術資産を買収し、自社のP-LNP技術と融合、次世代CAR-M治療の開発を加速。","ko":"ユナイテッド・イミュニティ株式会社의 IDA 공개 프로필입니다.","zh":"United Immunity 是一家專注於先天免疫的全球藥物研發公司。近日完成收購 Carisma Therapeutics 的技術資產，整合至其 Myeloid Targeting Platform™，以提升針對實體癌的體內 CAR-M 療法效果並降低細胞激素釋放症候群風險。"},"modified":"2026-06-14","published":"2026-06-14","info_table":[{"k":"関連リンク","v":"1 件"}],"description":"ユナイテッド・イミュニティは、自然免疫分野のグローバル創薬企業。Carisma Therapeuticsから技術資産を買収し、自社のP-LNP技術と融合、次世代CAR-M治療の開発を加速。"},"corp_src":"kokuzei_unique","houjin_source":"v6-name_norm+2sig","jp_corp_number":"6190001025121","houjin_bango_self":"6190001025121","houjin_match_name":"ユナイテッド・イミュニティ株式会社"},"owner_published":{"available":false,"published_at":null,"source":null},"freshness":{"observed_at":"2026-05-24T17:15:38.656Z","expires_at":null,"is_stale":null,"source":"entity.last_updated"},"provenance":{"source":"tqaeo.public.ida_entities_public.public_ids.owner_published","generated_at":"2026-06-15T08:50:09.358Z","owner_published_source":null,"contract_version":"owner-published-freshness/v1","sameAs_policy":"owner_published_does_not_upgrade_verification_level"},"verification_level":"strong","edge_summary":{"total_edges":1,"sameAs_eligible_edges":1,"strongest_edge_tier":"strong","public_id_count":1},"last_updated":"2026-05-24T17:15:38.656Z"}